フィブリノゲン濃縮物の世界市場規模：製品別、用途別、地域範囲別、予測

フィブリノゲン濃縮物の市場規模と予測

フィブリノゲン濃縮物の市場規模は、2024年に31億1,000万米ドルと評価され、2026年から2032年にかけてCAGR 5.64%で成長し、2032年には46億3,000万米ドルに達すると予測されています。

フィブリノゲン濃縮物市場は、人々の間で血液関連疾患が増加していることと、フィブリノゲン濃縮物に対する人々の受け入れが拡大していることから、かなりの成長が見込まれています。フィブリノゲン濃縮物の世界市場レポートは、市場の全体的な評価を提供します。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

世界のフィブリノゲン濃縮物市場の定義

フィブリノゲンは血漿中に存在する糖タンパク質で、肝臓で産生されます。フィブリノゲンは脊椎動物に存在し、血栓の形成を助けますが、フィブリノゲンのレベルが低いために血管内に血栓が形成されることがあり、これが血栓症を引き起こし、循環系を通る正常な血液の流れを妨げます。フィブリノゲンは、血液中のフィブリノゲンの濃度を低下させ、血栓を形成します。血栓症はまれな出血性疾患であり、軽度から重篤な出血を特徴とします。フィブリノゲン欠乏症には低フィブリノゲン血症、アフィブリノゲン血症、フィブリノゲン欠乏症の3つがあります。患者が大量に出血している場合、フィブリノゲン濃度は全血凝固の硬直性を高め、術後の輸血必要量を減少させます。

フィブリノゲン濃縮物の世界市場概要

この競争の激しい世界では、ライフスタイルの変化により人々の間でストレスが増加しており、その結果、血液関連疾患が増加しています。先天性フィブリノゲンは、血友病の発生を改善し、より優れたフィブリノゲン製品をもたらすこの市場で最大のシェアを占めると推定されています。先天性フィブリノゲン欠乏症のような出血に関連する疾患の患者に対するフィブリノゲン濃縮製剤の使用の増加は、この市場の成長を促進する主な要因です。今日、人々の健康に対する意識が高まり、健康を第一に考えるようになったことも、この市場の成長を促進する重要な要因です。

現在、凍結血漿や凍結沈殿物を含む従来のフィブリノゲン供給源の代わりに、フィブリノゲン濃縮物が企業とともに人々に広く受け入れられています。フィブリノゲン濃縮物市場は、フィブリノゲンの需要増加につながった患者人口の増加と様々な外科手術の使用のために増加しています。さらに、フィブリノゲン濃縮物は、先天性アフィブリノゲン血症、フィブリノゲン血症、低フィブリノゲン血症などの治療に使用される抗凝固剤を調製するために利用されています。

目次

第1章 世界のフィブリノゲン濃縮物市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 フィブリノゲン濃縮物の世界市場見通し

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 フィブリノゲン濃縮物の世界市場：製品別

• 概要
• 動物フィブリノゲン濃縮物
• ヒトフィブリノゲン濃縮物

第6章 フィブリノゲン濃縮物の世界市場：用途別

• 概要
• 先天性フィブリノゲン欠乏症
• 外科的処置

第7章 フィブリノゲン濃縮物の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 フィブリノゲン濃縮物の世界市場：競合情勢別

• 概要
• 各社の市場ランキング
• 主な発展戦略

第9章 企業プロファイル

• CSL Behring
• LFB Group
• ProFibix BV
• Baxter International Inc.
• Hualan Biological Engineering
• Harbin Pacific Biopharmaceutical Co. Ltd
• Green Cross Limited
• Shanghai Xinxing Medicine Co. Ltd.
• Green Cross Limited
• Shanghai Xinxing Medicine Co. Ltd.

第10章 付録

• 関連調査

Fibrinogen Concentrates Market Size And Forecast

Fibrinogen Concentrates Market size was valued at USD 3.11 Billion in 2024 and is projected to reach USD 4.63 Billion by 2032, growing at a CAGR of 5.64% during the forecast period 2026-2032.

The Fibrinogen Concentrates Market is expected to show considerable growth owing to increasing blood-related disorders among people and growing acceptance of people for Fibrinogen Concentrate. The Global Fibrinogen Concentrates Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Fibrinogen Concentrates Market Definition

Fibrinogen is a glycoprotein present in the blood plasma and this is produced by the liver. Fibrinogen is present in the vertebrates which helps in the formation of a blood clot, sometimes blood clot is formed inside the blood vessels because of a low level of fibrinogen which leads to thrombosis and this interrupts the normal blood flow through the circulatory system. It is also helpful for making medicines for the disease-related blood. Thrombosis is an infrequent bleeding disorder that can be characterized by mild to critical forms of bleeding. The three forms of fibrinogen deficiency are hypofibrinogenemia, afibrinogenemia, and dysfibrinogenemia. When the patient is heavily bleeding the fibrinogen concentration enhances the whole blood clot rigidness and decreases the postoperative transfusion requirements.

Global Fibrinogen Concentrates Market Overview

In this competitive world, there is increasing stress among the people due to changes in their lifestyle as a result of this there is an increase in blood-related disorders, Congenital Fibrinogen is estimated to hold the largest share of this market which results in a better occurrence of hemophilia and better fibrinogen products. Increasing the use of fibrinogen concentrates for patients with the disease-related to bleeding such as congenital deficiencies is the primary factor driving the growth of this market. Nowadays people are more aware of their health and consider health their first priority is another important factor driving the growth of this market.

Presently, instead of traditional fibrinogen sources including frozen plasma or cryoprecipitate, Fibrinogen Concentrate is broadly being accepted by the people along with the firms. The Fibrinogen Concentrates Market is increasing due to the growing patient population and use of various surgical procedures which has led to the increased demand for Fibrinogen. Moreover, The Fibrinogen concentrates are being utilized to prepare anti-coagulates which are used in the treatment of congenital afibrinogenemia, dysfibrinogenemia, hypofibrinogenemia, and others.

Global Fibrinogen Concentrates Market: Segmentation Analysis

The Global Fibrinogen Concentrates Market is Segmented on the basis of Product, Application, and Geography.

Fibrinogen Concentrates Market, By Product

• Animal Fibrinogen Concentrates
• Human Fibrinogen Concentrates

Based on Product, the market is segmented into Animal Fibrinogen Concentrates and Human Fibrinogen Concentrate. Human Fibrinogen Concentrate is estimated to hold the largest share of this segment during the forecasted period due to the increasing requirement for fibrinogen concentrate to treat bleeding disorders and congenital coagulation deficiencies.

Fibrinogen Concentrates Market, By Application

• Congenital Fibrinogen Deficiency
• Surgical Procedures
• ased on Application, the market is segmented into Congenital Fibrinogen Deficiency and Surgical Procedures. Congenital Fibrinogen is estimated to show the highest growth during the forecasted period owing to high incidences of hemophilia and increasing bleeding disorders among people. The safety proven by fibrinogen concentrates and advancements in fibrinogen products has also led to the growth of this segment in the Fibrinogen Concentrates Market.

Fibrinogen Concentrates Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of regional analysis, the Global Fibrinogen Concentrates Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is estimated to hold the largest share of this market because of the increasing burden of bleeding disorders and growing geriatric population and acquired hemophilia which is a rare autoimmune disorder is foremost in the geriatric population and a disease called Von Willebrand is one of the most common bleeding disorder which affects almost 1% of the population every year in the United States. These are the major factors contributing to the growth of the Fibrinogen Concentrates Market in this region.

Key Players

The "Global Fibrinogen Concentrates Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are CSL Behring, LFB Group, ProFibix BV, Baxter International Inc., Hualan Biological Engineering, Harbin Pacific Biopharmaceutical Co. Ltd, Green Cross Limited, and Shanghai Xinxing Medicine Co. Ltd. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• December 2021 - LFB plasma which is a part of LFB Group announced its acquisition of Immuno Tek Bio Centre in Florence, South California. LFB Group is a global biopharmaceutical company that develops and provides plasma-derived and recombinant products through its innovative technologies.
• January 2022 - GC Cell and Rivaara Immune Private Limited announced that they are about to enter into an exclusive licensing agreement, Rivaara Immune has agreed to develop and commercialize Immunecell-LC.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL FIBRINOGEN CONCENTRATES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL FIBRINOGEN CONCENTRATES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL FIBRINOGEN CONCENTRATES MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Animal Fibrinogen Concentrate
• 5.3 Human Fibrinogen Concentrate

6 GLOBAL FIBRINOGEN CONCENTRATES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Congenital Fibrinogen Deficiency
• 6.3 Surgical Procedures

7 GLOBAL FIBRINOGEN CONCENTRATES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL FIBRINOGEN CONCENTRATES MARKET, BY COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 CSL Behring
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 LFB Group
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 ProFibix BV
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Baxter International Inc.
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Hualan Biological Engineering
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Harbin Pacific Biopharmaceutical Co. Ltd
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Green Cross Limited
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Shanghai Xinxing Medicine Co. Ltd.
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Green Cross Limited
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Shanghai Xinxing Medicine Co. Ltd.
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research